Chugai Pharmaceutical and Gero have signed a joint research and license agreement to co-develop novel treatments targeting age-related diseases. Under the terms, Gero will lead early-stage research efforts, while Chugai holds an exclusive option to in-license promising preclinical candidates for further development and commercialisation.

The partnership builds on the companies’ shared interest in addressing mechanisms of aging and related disorders. Specific therapeutic areas or financial details were not disclosed in the release.